Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes
November 27, 2023 09:00 ET
|
Biodexa Pharmaceuticals PLC
Cardiff , Nov. 27, 2023 (GLOBE NEWSWIRE) -- 27 November 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to...
DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 14, 2023 07:30 ET
|
DMK Pharmaceuticals Corporation
Rebranded company to DMK Pharmaceuticals and appointed inaugural, passionate and committed leadership team to execute on new strategy to reduce opioid related deaths through enhanced sales of ZIMHI®...
Compass Therapeutics to Participate in Upcoming Investor Events
November 07, 2023 08:00 ET
|
Compass Therapeutics
BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Global Cold Storage Construction Market to Reach Value of USD 35.48 Billion by 2032 | Emergen Research
November 06, 2023 09:19 ET
|
Emergen Research
Vancouver, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The global cold storage construction market is projected to reach a market size of USD 35.48 Billion by 2032, and revenue growth is expected to be...
Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit
November 06, 2023 07:30 ET
|
Scinai Immunotherapeutics Ltd.
JERUSALEM, Nov. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced that the Israel Innovation Authority (IIA) has approved a non-dilutive grant...
Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update
October 31, 2023 08:23 ET
|
Scinai Immunotherapeutics Ltd.
JERUSALEM, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative...
Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023
October 04, 2023 07:30 ET
|
Scinai Immunotherapeutics Ltd.
JERUSALEM, Oct. 04, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced that it will be showcasing its CDMO services at CPHI Barcelona, one of the...
Fusion Inhibitors Market Revenue to Cross USD 7.2 billion by 2031, Exhibiting a 14.2% CAGR: TMR Report
October 04, 2023 03:52 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The fusion inhibitors market attained US$ 295.3 million in 2021. The market is likely to...
Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma
October 03, 2023 08:30 ET
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma Biodexa Pharmaceuticals PLC, (Nasdaq:...
Syneos Health Appoints Colin Shannon as Chief Executive Officer
October 03, 2023 08:00 ET
|
Syneos Health, Inc.
Syneos Health today appointed Collin Shannon as its new CEO. Michelle Keefe remains on Company Board and member of its executive leadership team.